Prevent C. difficile infection in high-risk hospital patients
Part of Infections clinical trials.
This trial tests whether giving prevention right away can stop C. difficile infection from developing in people identified as high risk after a VRE swab. It may help reduce stomach infection and serious complications during hospital stay.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in the ICU or an oncology (cancer) unit
- A screening swab test showed you carry C. difficile bacteria (even if you don’t feel sick)
- You were identified as a “carrier” based on the hospital testing (VRE swab)
- The study is for people who are admitted to these specific unit types (ICU or oncology)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how Clostridioides difficile (C. diff) affects healthy people by intentionally giving a controlled dose. The goal is to understand the infection better and help develop future treatments or vaccines.
This trial tests whether giving vancomycin through a tube into the stomach can prevent a serious gut infection called C. diff in people who are very sick in the ICU and taking antibiotics. If you qualify, you might receive this medicine to lower your risk.
This trial tests whether taking vancomycin by mouth can prevent another C. diff infection when you need to take other antibiotics. It’s for patients who recently had C. diff and are about to start a new antibiotic course.
This trial tests a new medicine called VE303, a live bacterial therapy, to prevent C. diff infections from coming back. It is for people who have had C. diff at least once in the last 6 months, or who are at high risk for a repeat infection due to age or other health problems.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This trial tests whether a gradual decrease (taper) of vancomycin can stop C. diff infections from returning. It’s for adults with their first or second C. diff infection who can take pills by mouth.
Hear when a new C. Difficile trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.